Bücher der Reihe Cancer Drug Discovery and Development

As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR.

Significance of Stem Cells to Tumor DevelopmentCancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve.

This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint.

Reviews the role of HGFs in clinical practice, explains the molecular basis of their effects, and considers potential developments. This book focuses on the use of HGFs in oncology, describing their application to patients with lung cancer, Hodgkin's and nonhodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, and more.

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.

Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.

The recent explosion of knowledge gained from genes capable of causing cancer have opened up new avenues for designing anticancer drugs. This volume describes the efforts of several groups in the design and evaluation of these inhibitors.

The past few years have witnessed an astonishing international effort that established the role of some 20 new molecules in apoptosis and added activation or suppression of apoptosis to the accepted biological functions of a great many others already familiar in cancer biology.

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it.

The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies.

A variety of cutting-edge imaging techniques, including their use for best practice, are addressed in this book. The book also provides examples of results found in both pre-clinical and clinical studies. This comprehensive text covers the entire spectrum of in vivo imaging for oncology.

Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs.

Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types.

While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.

A comprehensive review of the recent developments in DNA repair research that have potential for translational applications.

A comprehensive review of the recent developments in DNA repair research that have potential for translational applications.

Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types.

The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island).

Leading scientists summarize the latest findings on signal transduction and cell cycle regulation and describe the effort to design and synthesize inhibiting molecules, as well as to evaluate their biochemical and biological activities.

This book provides insight into established practices and research into apoptosis and senescence. The volume thoroughly examines novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics that still hold mysteries for researchers.

This book provides insight into established practices and research into apoptosis and senescence. The volume thoroughly examines novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics that still hold mysteries for researchers.

This book describes the principles underlying targeted hormonal treatments, assesses the actions of new and established agents, and illustrates the new applications of hormonal chemoprevention for breast cancer.

This book describes the principles underlying targeted hormonal treatments, assesses the actions of new and established agents, and illustrates the new applications of hormonal chemoprevention for breast cancer.

Transforming Growth Factor- ss in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ss (TGF- ss) in cancer treatment and therapy. The companion volume details the role of TGF- ss on basic and clinical biology.

Transforming Growth Factor- ss in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ss (TGF- ss) in cancer treatment and therapy.

While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.

This book presents the first comprehensive exploration of the dynamic potential of microtubules anti-cancer targets. Written by leading anti-cancer researchers, this groundbreaking volume collects the most current microtubule research available and investigates the potential of microtubules in cancer therapy.